Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candida albicans antigen
- Development stage
- Approved
- Lead developer
- Nielsen BioSciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intralesional
01
Overview
Candida albicans antigen is an investigational biological immunotherapeutic agent derived from the *Candida albicans* fungus, primarily utilized for the treatment of various types of warts, including plane warts (verruca plana). Administered via intralesional injection, the antigen acts by stimulating a potent local cell-mediated immune response, characterized by a delayed-type hypersensitivity reaction. This immune activation facilitates the recognition and destruction of human papillomavirus (HPV)-infected cells, often resulting in the clearance of both the injected lesion and distant, untreated warts. South Valley University has conducted comparative clinical trials evaluating the efficacy of intralesional Candida antigen against other modalities such as autologous platelet-rich plasma (PRP) for the management of plane warts.
- Brand names
- Candin
- Other names
- C. albicans antigenCandida antigenCandida albicans immunotherapy
02
Targets
MHC II (Major histocompatibility complex class II receptor)TCR–MHC II (TCR–MHC class II complex)
Beyond the preview
Go deeper on candida albicans antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candida albicans antigen.